NCT04551066 2025-10-21To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)Incyte CorporationPhase 3 Terminated252 enrolled 18 charts
NCT04551053 2025-10-02To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Incyte CorporationPhase 3 Terminated177 enrolled 15 charts